Primal Study

Precision Medicine Randomized Clinical Trial Comparing
Molecular Tumor Board Assisted Care to Usual Care (PRiMAL)


This trial will compare Molecular Tumor Board (MTB) assisted care to usual care for patients who have newly diagnosed histologically or cytologically confirmed stage IIb-IV Non-Small Cell Lung Cancer (NSCLC) and are planning to undergo treatment for their cancer.

Molecular Tumor Board

The Markey Cancer Center Molecular Tumor Board is a forum for experts to review genetic abnormalities to provide patient-specific targeted therapies.
Learn More

PRiMAL Website

To learn more about the PRiMAL study, visit the website.
Learn More
Precision Medicine Symposium


8th Annual Precision Medicine Symposium
February 23, 2024  |  Griffin Gate Marriott Resort and Spa

This symposium highlights clinical advances in precision medicine and cancer health disparities.


NCI Comprehensive Cancer Center - A Cancer Center Designated by the National Cancer Institute

Markey Cancer Center is designated by the National Cancer Institute as a Comprehensive Cancer Center – a distinction that recognizes our commitment to accelerating precision cancer research and care to patients. We are the first and only NCI-Comprehensive Cancer Center in Kentucky, and one of 57 in the nation.